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S U M M A R Y
We present a case report of cryptococcal immune reconstitution syndrome (IRS), in a non HIV infected
patient, which we treated with hydroxychloroquine with successful results. We brieﬂy review
cryptococcal IRS, possiblemechanisms of action of hydroxychloroquine as an immunomodulatory agent,
and its potential role in management of IRS.
 2010 International Society for Infectious Diseases. Published by Elsevier Ltd. All rights reserved.
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Disseminated cryptococcosis is seen most commonly in the
setting of human immunodeﬁciency virus (HIV) infection, often
with very lowCD4 counts and high viral loads. Its occurrence in the
non-HIV setting is less common and is seen mostly with organ
transplantation and diseases that are associated with altered cell-
mediated immunity, either directly or through immunomodulato-
ry drug therapy.
While the immune reconstitution syndrome (IRS) in the
setting of highly active antiretroviral therapy and cryptococcal
disease is well described, its occurrence in the non-HIV setting is
less common. Since the central nervous system (CNS) is not
as commonly involved in the non-HIV patients, so also IRS in
this setting may present in myriad ways. These include skin
nodules, ocular lesions, bone and joint involvement, liver
lesions, bladder lesions, lung inﬁltrates, and also hypercalcemia
from excessive 1,25-dihydroxyvitamin D production by the
macrophages in a granulomatous reaction that occurs with
immune reconstitution.* Corresponding author. Tel.: +1 270 799 3257; fax: +1 443 444 4997.
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doi:10.1016/j.ijid.2010.09.006Steroids have been used in some cases of life-threatening IRS.
Nonsteroidal alternatives for treating ﬂorid IRS have not been
adequately studied. We present a case of cryptococcal IRS in the
setting of steroid withdrawal, presenting with nodules, lung
inﬁltrates and hypercalcemia, which we chose to treat with
hydroxychloroquine with successful results.
2. Case report
A 79-year-old Caucasian femalewas admittedwith a cough that
was productive of scant clear phlegm and shortness of breath. She
had a small area of cellulitis on the dorsum of the right hand
following extravasation of ﬂuids from an intravenous cannula
placed during a recent admission for pneumonia. She also had
painful and pruritic skin lesions scattered over various parts of her
body, but primarily localized to her extremities; these had been
present for 1 week, but had been rapidly worsening over the 2–3
days prior to admission. She had no complaints of wheezing, chest
pain, fever, or edema. In the emergency department, shewas found
to be hypoxemic with a possible left-sided pulmonary inﬁltrate on
chest radiography. She was admitted and started on intravenous
levoﬂoxacin for presumed community-acquired pneumonia.
Her past medical history was notable for myasthenia gravis,
which had been diagnosed 6 months previously. She was beingses. Published by Elsevier Ltd. All rights reserved.
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Figure 1. Initial skin lesions, which looked like an extravasation from an intravenous line (left), and a large plaque on the patient’s right forearm.
Figure 2. Computerized tomography scan of the chest demonstrating bilateral
interstitial and alveolar inﬁltrative pattern during the immune reconstitution
phase.
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mycophenolate mofetil, approximately 1 week prior to presenta-
tion. No thymoma was present on imaging. She also had chronic
renal insufﬁciency, with baseline creatinine of 1.5–1.6 mg/dl (132–
141 mmol/l) and primary hypothyroidism. Throughout her life-
time, she had never used any tobacco products, alcohol, or illicit
drugs. Hermedications included pyridostigmine 60 mg three times
a day, prednisone 20 mg per day, levothyroxine 50 mg per day, and
carvedilol 6.25 mg twice a day.
On physical examination, she appeared to be inmild respiratory
distress, with a respiratory rate of 24/min and bedside oxygen
saturation of 91% on room air by pulse oximetry. Her blood
pressure was 130/80 mmHg and heart rate was 80/min. A skin
examination was remarkable for nodular and plaque-like ery-
thematous lesions scattered on her arms, legs, and back. These
lesions were ﬁrm to palpation and minimally tender (Figure 1). No
mucosal lesions or enlarged lymph nodes were noted. She also had
fatigable ptosis and minimal proximal motor weakness on
neurological assessment, with strength of 4+/5 on the Medical
Research Council (MRC) scale. Her chest examination showed
clinical signs of left lower lobe consolidation.
Laboratory ﬁndings were notable for a creatinine level of
1.7 mg/dl (150 mmol/l). Arterial blood gases showed respiratory
alkalosis and hypoxia.
Sputum and blood cultures were negative initially for bacteria,
mycobacteria, and fungi. Despite being started on antimicrobial
therapy, she continued to have worsening shortness of breath.
This was initially thought to be due to worsening of her
myasthenia, and her corticosteroid dose was increased by 30%.
With worsening pulmonary inﬁltrates on chest roentogram and
no microbiological conﬁrmation of infection, a diagnostic
bronchoscopy with lavage (BAL) was performed. In addition,
her skin lesions were biopsied. The bronchial washings were
negative for Gram stain and acid-fast bacillus smear and culture.
The BAL specimens stained positive for yeast on silver stain, and
the BAL cultures became positive for Cryptococcus neoformans.
Meanwhile, blood cultures drawn on hospital day 1 became
positive for yeast, which was later speciated as C. neoformans. The
biopsied lesions also stained positive for yeast, later speciated as
C. neoformans. She underwent a lumbar puncture to rule out
meningitis and her cerebrospinal ﬂuid (CSF), despite being
unremarkable with 3  106/l cells, 42 mg/dl protein and 54 mg/
dl (3mmol/l) glucose, stained positivewith India ink for yeast. The
CSF culture subsequently grew C. neoformans, with positive CSF
cryptococcal antigen at 1:1024 dilution.
In view of her disseminated cryptococcosis, she was started on
liposomal amphotericin B. She was tapered off her steroids over 1
week, and continued on optimized doses of pyridostigmine. She
felt subjectively better, with decreased shortness of breath and a
subjective sense of well being. She was regularly monitored with
bedside testing of her respiratory function to detect anyworseningof her myasthenia gravis. The skin nodules became ﬂatter over
time, and no new nodules erupted. A repeat CSF analysis done after
4 weeks of antifungal therapy revealed a reduced cryptococcal
antigen titer, down to 1:128 dilution.
After 6 weeks of amphotericin, she developed new crops of
lesions over her buttocks and back that were similar in appearance
to her original lesions. The new lesions were also painful and
pruritic. She also started to develop increasing shortness of breath
and a dry cough. Imaging of her chest revealed worsening
inﬁltrates with an interstitial pattern (Figure 2). She also had a
worsening liver function proﬁle, with elevated transaminases to
the 400 IU/l range and with alkaline phosphatase increasing from
normal to over 1200 U/l (20 nkat/l) over a 1-week period; however,
total bilirubin stayed in the normal range. These changes were
consistent with an inﬁltrative pattern of liver disease, though liver
imaging showed no altered echotexture.
She underwent a repeat bronchoscopy, which was again
negative for Gram-reactive bacteria or acid-fast organisms. Her
new skin lesions, which were biopsied again, revealed abundant
cryptococci on staining. These did not however grow on fungal
culture. The histopathology of these lesions revealed a transfor-
mation from a necrotic pattern in the initial specimens to a
granulomatous pattern of inﬂammation (Figure 3).
Our concern was resistant cryptococcosis versus a possible
immune reconstitution syndrome occurring in the setting of
steroid withdrawal. Though C. neoformans resistance to ampho-
tericin is unusual, susceptibility testing (broth microdilution
method) was performed on the original samples to rule out that
possibility. These tests showed the Cryptococcus species to be
sensitive to all antifungals tested, including all azole drugs.
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Figure 3. Photomicrographs of biopsy specimens of skin lesions before (left, 20, periodic acid–Schiff stain) and after (right, 20, mucin stain) initiation of antifungal therapy.
There is evolution of histology from one of inﬂammation with abundant yeasts on the left to granulomatous inﬂammation with evidence of giant cell formation on the right.
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calcium 11.1 mg/dl (2.78 mmol/l), albumin 1.7 g/dl (17 g/l) and
ionized calcium1.65mmol/l), which seemedunexplained, especial-
ly in the setting of an acute illness. Further investigations led to the
detection of low 25-hydroxyvitamin D (total 18 ng/ml, normal
values25–80ng/ml)and intactparathormone (iPTH) levels (iPTH<3
pg/ml, normal values 12–65 pg/ml). However, the 1,25-hydro-
xyvitamin D level was 76 pg/ml (normal values 18–78 pg/ml).
The consensus of the treating team was to hold off on starting
prednisone in view of the development of disseminated illness in
the setting of being on relatively moderate doses of prednisone on
initial presentation. The low iPTH and the ratio of 1,25- to 25-
hydroxyvitamin D levels being more than 4 (normal 1.25) led to
the speculation that the hypercalcemia was possibly related to a
vitamin D-related process, often seen in the granulomatous
lesions. Hydroxychloroquine has been found to be beneﬁcial in
the treatment of hypercalcemia in granulomatous diseases, and it
was decided that this was a safer alternative to high dose
corticosteroids. After initiation with hydroxychloroquine the
patient made remarkable progress. Her skin lesions decreased
signiﬁcantly over the ensuing 2 weeks and her shortness of breath
improved, as did her chest radiographs. Liver function tests
returned to baseline levels. During this time, her myasthenia
remained stable with no need for escalation of pyridostigmine
doses. The antifungal regimen was changed to ﬂuconazole, on
which she was subsequently discharged to a rehabilitation unit.
This patient’s course is unique for a number of reasons –
disseminated cryptococcosis occurring in a non-HIV setting with
moderate doses of prednisone, immune reconstitution occurring in
the setting of steroid withdrawal, hypercalcemia occurring with
immune reconstitution in the setting of granulomatous inﬂamma-
tion, and treatment of immune reconstitution and hypercalcemia
with hydroxychloroquine.
3. Discussion
Cryptococcosis is caused by the dimorphic fungus C. neofor-
mans. Cryptococcal infection can vary in severity from a localized
pulmonary acute infection with symptoms of fever and cough to
disseminated disease. Host cell-mediated immunity is a primary
determinant of the severity of disease.
At present, more than 80% of cryptococcosis cases worldwide
are associated with HIV infection. With the availability of potent
antiretroviral therapy, the incidence of cryptococcosis in the HIV-
infected population has decreased signiﬁcantly. However, the
incidence of cryptococcal infection in non-HIV hosts has not
changed.1
Another documented risk factor for acquired cryptococcal
infections is organ transplantation. Among patients who undergosolid organ transplantation, cryptococcosis is the third most
common invasive fungal infection after candidiasis and aspergil-
losis.2,3 Finally, other medical conditions that compromise host
immunity or are associated with treatment with corticosteroids
will predispose to cryptococcosis, such as systemic lupus
erythematosus, sarcoidosis, hematological malignancies, diabetes
mellitus, chronic pulmonary disease, lung cancer, renal failure, and
cirrhosis.3,4 Baddley et al. found that receiving corticosteroids
equivalent to more than 20 mg of prednisone for more than 60
days prior to diagnosis was associated with an increased risk of
disseminated cryptococcosis in non-HIV patients.5
In a study by Pappas et al. of 306 HIV-negative patients with
cryptococcosis at 15medical centers in the USA from 1990 through
1996, corticosteroid treatment was the most common underlying
condition predisposing to cryptococcosis (28%), followed by solid
organ transplant (18%) and rheumatologic disease (13%).6
The CNS is the most common site of disseminated disease in
HIV-infected patients. But CNS involvement in pulmonary
cryptococcosis in non-HIV-infected patients is less common. In
the same study by Pappas et al., among patients with non-HIV
cryptococcosis, constitutional symptoms were seen in 57%, skin
manifestations in 9%, pulmonary symptoms in 41%, and CNS
symptoms in 52% of patients.6
A strong cell-mediated immune response is believed to be
crucial for containing cryptococcal infection.7 At the same time, an
excessive immune response can cause clinical worsening, consis-
tent with the IRS, which has been seen in up to 33% of HIV-
associated cryptococcosis. Achieving this so-called Goldilocks
paradigm of neither too much nor too little immune response
rarely occurs in the host with a dysfunctional immune system.
Thus, an entire spectrum of illness, as seen in our patient, can
result.8 C. neoformans-associated IRS typically presents as lymph-
adenitis, enhancing CNS lesions, or skin or soft tissue lesions.9 A
hallmark of IRS lesions is a granulomatous change, of which Th1
cells are important mediators.10
The use of corticosteroids in the management of cryptococco-
sis-associated IRS has been proposed,11 especially when inﬂam-
mation at the site of involvement severely impairs organ function
(e.g., eye, liver, brain, or lungs) and becomes life-threatening.12
One must weigh the risks and beneﬁts of using steroids in
individual cases before deciding on this therapy.
Interestingly, some case reports13 implicate hypercalcemia
occurring during treatment of cryptococcosis as a marker of
immune reconstitution. Hypercalcemia in fungal infections is
associated with granulomatous inﬂammatory reactions.14 This is
thought to be the result of the extrarenal production of 1,25-
dihydroxyvitamin D from the 1-hydroxylation of 25-hydroxyvi-
tamin D by macrophages stimulated by interferon-gamma (IFN-
g)15,16 in the granuloma. We speculate that this mechanism
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concurrently with the change in lesion histopathology from
necrosis to one of granulomatous inﬂammation.
This 1-hydroxylation step is inhibited by hydroxychloroquine
and this drug has been used in reported cases for controlling the
hypercalcemia in sarcoidosis where a similar mechanism is
operative.17–19 Various mechanisms have been proposed and
studied to account for the immune regulatory role of chloroquine.
Being a weak base, chloroquine accumulates in endosomes, raising
their pH, and may affect their function.20 In patients with
cryptococcal immune reconstitution, the inﬂammation is proposed
to be a reversal of the predominantly Th2 response to a pro-
inﬂammatory Th1 response, of which IFN-g and tumor necrosis
factor-alpha (TNF-a) are chief mediatory cytokines.21 It is possible
that chloroquine and hydroxychloroquine can inhibit this cytokine
by lysosomotropic and other pathways. In fact chloroquine has
been shown to decrease the production of IFN-g, TNF-a,
and interleukin-6 (IL-6) in lipopolysaccharide- or phytohemagglu-
tinin-stimulated peripheral blood mononuclear cells.22 Chloro-
quine also prevents T cell activation by preventing Toll-like
receptor (TLR)-mediated signaling by plasmacytoid dendritic cells
(pDC) and downstream synthesis of interferon-alpha (IFN-a).23
Chloroquine may also inﬂuence humoral immunity, as evidenced
by decreased antibody responses to pre-exposure human diploid
cell vaccine when co-administered with chloroquine.24 Interest-
ingly, chloroquine has also been shown to have in vitro anti-HIV
activity by affecting the production of new viral envelope
glycoproteins. It is plausible that this may decrease the epitope
burden for immune reconstitution as well.25
As evident from the above discussion, some of these mechan-
isms of action of chloroquine may be speciﬁc for the pathways
operative in IRS. We treated our IRS patient with hydroxychlor-
oquine, with remarkable clinical results.We have to admit that our
observation is strictly a hypothesis, as there cannot be a control for
this type of data and the natural course of immune reconstitution
improves once the infection (Cryptococcus in this case) is treated.
However, our experience with this patient offers insights into
potential mechanisms of action. Advances in our understanding of
the mechanisms of action of chloroquine as an immunomodulato-
ry drug, past experience with its use in other disorders of immune
function, and its relatively low and well-established side-effect
proﬁle suggest the need for further investigation into its potential
use in immune reconstitutive states.
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